Mylan Stock Buy Or Sell Instant

Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues.

Recent FDA warnings and import alerts regarding manufacturing facilities in India (Indore and Nashik) continue to impact EBITDA estimates.

Viatris offers a solid dividend yield of approximately 3.24% , which may appeal to income-focused investors. mylan stock buy or sell

Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ).

The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026. Analysts are concerned about a lack of a

~$14.67, indicating a slight forecasted downside of roughly -1% . Target Range: High of $18.00 and a low of $10.00 . Investment Case: Buy vs. Sell Buy Case (Bullish) Sell/Hold Case (Bearish)

To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026) Mylan (formerly NASDAQ: MYL) no longer exists as

AI responses may include mistakes. For financial advice, consult a professional. Learn more